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Background: The aim of this study is to determine the preferences and perspectives regarding the Quantiferon TB
Gold test for the diagnosis of tuberculosis (TB) in India. A survey was distributed among 46 uveitis specialists,
rheumatologists, and pulmonologists with a minimum of 2 years experience in the management of tuberculosis, in
order to restrict the respondents to specialists who have used this test in their practice in the diagnosis of
tuberculosis. Topics included demographics, usage, logistics, effectiveness, and preferences related to the
Quantiferon TB Gold test.
Results: Among the 37 responders, there were 19 uveitis specialists, 9 rheumatologists, and 9 pulmonologists with
the majority having more than 7 years of experience in treating tuberculosis. Latent TB was the most common type
of tuberculosis reported by 81% of the responders. Although 92% agree that Quantiferon TB Gold assay is used for
the diagnosis of latent TB, only 32% use this test always in their practice. Limiting factors include the higher cost
(35.14%), limited data from countries endemic for TB and hence limited interpretation of results (32.43%), the
inability to differentiate active and latent TB (32.43%), and technical issues related to the test (18.92%). A
combination of the Mantoux test and Quantiferon TB Gold test was the preferred test for investigation in 51% of
the responders rather than solo tests.
Conclusions: Within this group of specialists dealing with different forms of tuberculosis, perspectives of this test
and preferences are many. The increased cost and limited data from India with respect to interpretation of the
results are the most common limiting factors in using this test.
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Interferon gamma release assays (IGRAs) are new
immune-based in vitro tests for detecting Mycobacterium
tuberculosis (MTb) infection [1,2]. They are based on the
detection of interferon gamma (IFN-γ) released by sensi-
tized T cells on stimulation with very specific antigens,
early secretory antigen target-6 and culture filtrate pro-
tein-10, both derived from a very specific region of MTb,
the region of difference 1 (RD1). This segment (RD1) is
deleted from all strains of BCG and the majority of envir-
onmental mycobacteria (except Mycobacterium kansasii
[3], Mycobacterium szulgai, Mycobacterium marinum,
Mycobacterium flavescens, and Mycobacterium gastrii).* Correspondence: kalpana@prabhaeyeclinic.com
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in any medium, provided the original work is pThe two IGRAs that are available commercially include
the T-Spot TB test (based on the ELISpot technology to
directly count the number of IFN-γ-secreting T cells) and
Quantiferon TB Gold In-Tube test (based on the ELISA
technology, which measures the concentration of IFN-γ
secretion; Cellestis Limited, Carnegie, Victoria, Australia).
As these tests are more popular in the developed coun-
tries [4-9], their utility in a TB-endemic country like India
is not clear. This is due to the limited data available on the
utility of these tests from this part of the world [10-14].
Quantiferon TB Gold and Quantiferon TB Gold In-Tube
tests are now available in India. The tests are being incor-
porated into practice as a result of their success in the
developed countries. The aim of this survey is to deter-
mine the preferences and perspectives regarding the
Quantiferon TB Gold test for the diagnosis of tuberculosis
(TB) in India.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Type of tuberculosis seen
Active TB was most frequently seen by pulmonologists
(100%) and rarely by ophthalmologists (73.7%) and rheu-
matologists (89.8%). Latent TB was most frequently seen
by ophthalmologists (94.7%) and rheumatologists (77.8%).
This was clinically significant with a p value of 0.001
(Pearson chi-square test).
Usage of this test
Although 92% agree that Quantiferon TB Gold assay is
used for the diagnosis of latent TB, only 59% of respon-
dents use this test routinely in their practice. This is
slightly less than 62%, who use Mantoux test routinely in
their practice. Ophthalmologists and rheumatologists use
this test more often than pulmonologists (p = 0.024).
Mantoux test is done routinely on all patients with sus-
pected tuberculosis by ophthalmologists and rheumatolo-
gists in contrast to pulmonologists (p = 0.001). A
Mantoux test is ‘always’ performed prior to starting
immunosuppressants by 51% of respondents. This is in
contrast to only 38% who always perform Quantiferon TB
Gold test prior to starting immunosuppressants. Forty-six
percent rarely treat a patient of suspected TB on the basis
of a positive Mantoux test alone. This is similar to 43%
who rarely treat a patient with suspected TB on the basis
of a positive Quantiferon TB Gold test. Fifty percent of
ophthalmologists and rheumatologists sometimes treat a
patient with suspected tuberculosis on the basis of Quan-
tiferon TB Gold test alone in comparison to 11.1% of pul-
monologists (p = 0.049). Sixty-two percent of the
respondents rated their experience with Quantiferon TB
Gold test for suspected TB in India non-comparable with
the results projected by the developed world. The pre-
ferred test for investigation in suspected tuberculosis is a
combination of Mantoux test and Quantiferon TB Gold
test in 51% of the responders in contrast to solo tests.
Technical and logistic issues pertaining to the test
The test was not available in their own center in 81% of
the respondents and had to be referred to a local labora-
tory in their own city (70%) or a laboratory outside the
city (24%). The remaining (5%) was not sure where the
sample is sent. In 65%, the cost of this test was equal to
or more than Rs. 2,000/− (i.e., around $50). When asked
regarding the frequency of ‘indeterminate’ results (al-
ways, sometimes, or never), the majority (76%) voted for
‘sometimes.’ When asked, ‘In what categories did they
see an indeterminate result,’ the most common answer
(86%) was ‘not sure’.
Limitations of the test
The most common limitation of this test was the in-
creased cost of the test (35.14%). Of the responders,35.14% felt there was lack of enough data available from
countries like India, which is endemic for TB, and hence
the interpretation of the result was difficult; 18.92% felt
that the test could not differentiate between active and la-
tent TB infection; 18.92% felt technical errors while trans-
portation or storage, poor quality control in different
laboratories, and non-availability of the test in many areas
were limitations of the test; 13.51% felt the test is mainly
for latent TB and not active TB; 8.1% felt this test was no
different from Mantoux test; 2.7% felt that this test cannot
be used for monitoring treatment; and 2.7% felt that it is
difficult to predict who will progress to active TB.
Results of the survey questionnaire in the three groups
of responders are compiled in Table 1.
Discussion
From this study, it is quite possible that there is a differ-
ence in the perception of Quantiferon TB Gold test by
ophthalmologists, rheumatologists, and pulmonologists.
This is probably due to the fact that ophthalmologists
and rheumatologists see more of latent TB in their prac-
tice and depend on indirect evidences like Mantoux test
and Quantiferon TB Gold test for a diagnosis, while the
pulmonologists see active TB more often and depend on
direct evidences like biopsy or culture for a diagnosis of
TB and hence rarely use Mantoux test and Quantiferon
TB Gold test in their practices.
Regarding the availability, this test is available in major
cities in India. Both the second generation (Quantiferon
TB Gold) and the third generation (Quantiferon TB
Gold In-Tube) are available in India. Respondents who
were using the second-generation test could have shifted
over to the third generation in the course of time. As
many of the respondents were not sure regarding the
generation of the test used, this survey could not reveal
the test used. This may have altered the overall percep-
tion of this test to a small extent. We do understand that
the indeterminate results and false positives are lesser in
the third-generation tests. However, this survey can be
used as a platform to plan prospective studies in future.
High cost is a key issue. This is one of the most im-
portant limiting factors in a developing country like
India. Thus, it is not feasible for individual laboratories
to do this test unlike the more cost-effective Mantoux
test. As a result, blood samples need to be transported
to the laboratories. Quality control becomes an import-
ant factor for accurate results.
From the survey results, it is noted that less than 50%
of the respondents base their treatment on the basis of a
positive Mantoux test or positive Quantiferon TB Gold
test alone as of now. This is probably due to the high
prevalence of latent infection in an endemic country like
ours. Unlike the developed world, we do not have
enough evidence regarding the interpretation of this test











1 Do you see active TB
routinely in your practice
Frequently 5 (26.3) 9 (100) 1 (11.1) 15 (40.5) 0.001
Rarely 14 (73.7) 0 8 (88.9) 22 (59.5)
2 Do you see latent TB
routinely in your practice
Frequently 18 (94.7) 5 (55.6) 7 (77.8) 30 (81.1)
Rarely 1 (5.3) 4 (44.4) 2 (22.2) 7 (18.9)
3 Does your center do the
Quantiferon TB Gold test in
your own laboratory
No 14 (73.7) 9 (100) 7 (77.8) 30 (81.1)
Yes 5 (26.3) 0 (0) 2 (22.2) 7 (18.9)
4 If your center does not do
this test, is the test readily
accessible to you
No 0 (0) 0 (0) 2 (22.2) 2 (5.4)
Yes 19 (100) 9 (100) 7 (77.8) 35 (94.6)
5 Do you send the blood
sample for this test to a
laboratory outside your city
No 13 (68.4) 7 (77.8) 6 (66.7) 26 (70.3)
Not sure 1 (5.3) 0 (0) 1 (11.1) 2 (5.4)
Yes 5 (26.3) 2 (22.2) 2 (22.2) 9 (24.3)
6 What is the approximate cost
of the test to your patient
Above Rs. 2,000/− 12 (63.2) 6 (66.7) 6 (66.7) 24 (64.9)
Below Rs. 1,000/− 0 (0) 1 (11.1) 0 (0) 1 (2.7)
Between Rs. 1,000/−
and Rs. 2,000/−
7 (36.8) 2 (22.2) 3 (33.3) 12 (32.4)
7 Do you do a Mantoux test
routinely on all patients with
suspected TB
Always 19 (100) 1 (11.1) 3 (33.3) 23 (62.2) 0.001
Sometimes 0 (0) 8 (88.9) 6 (66.7) 14 (37.8)
Never 0 (0) 0 (0) 0 (0) 0 (0)
8 Do you consider Mantoux
test a criterion for starting
a patient on ATT in
suspected TB
Always 7 (36.8) 0 (0) 1 (11.1) 8 (21.6)
Never 2 (10.5) 2 (22.2) 3 (33.3) 7 (18.9)
Sometimes 10 (52.6) 7 (77.8) 5 (55.6) 22 (59.5)
9 Do you use Quantiferon TB
Gold test in your practice
Never 1 (5.3) 2 (22.2) 0 (0) 3 (8.1)
Routinely 8 (42.1) 0 (0) 4 (44.4) 12 (32.4)
Sometimes 10 (52.6) 7 (77.8) 5 (55.6) 22 (59.5)
10 How often do you get
indeterminate as a result in
the Quantiferon TB Gold test
Always 1 (5.3) 0 (0) 0 (0) 1 (2.7)
Never 5 (26.3) 3 (33.3) 0 (0) 8 (21.6)
Sometimes 13 (68.4) 6 (66.7) 9 (100) 28 (75.7)
11 In what categories do you
see indeterminate result in
the Quantiferon TB Gold test
(can tick >1 option)
Age < 18 years 1 (5.3) 1 (11.1) 0 (0) 2 (5.4)
Age > 60 years 0 (0) 0 (0) 1 (11.1) 1 (2.7)
Between ages
18 to 60 years
3 (15.8) 0 (0) 0 (0) 3 (8.1)
Not sure 15 (78.9) 8 (88.9) 8 (88.9) 31 (83.8)
11 Do you perform Mantoux




Always 17 (89.5) 2 (22.2) 0 (0) 19 (51.4)
Never 2 (10.5) 3 (33.3) 5 (55.6) 10 (27)
Sometimes 0 (0) 4 (44.4) 4 (44.4) 8 (21.6)
12 Do you perform Quantiferon
TB Gold test routinely in all
patients prior to starting
immunosuppressants
(not biologics)
Always 3 (15.8) 0 (0) 0 (0) 3 (8.1)
Never 6 (31.6) 6 (66.7) 5 (55.6) 17 (45.9)
Sometimes 10 (52.6) 3 (33.3) 4 (44.4) 17 (45.9)
13 Your preferred investigation
in suspected TB in your
subset of patients
Both 15 (78.9) 2 (22.2) 2 (22.2) 19 (51.4)
Mantoux test 3 (15.8) 3 (33.3) 3 (33.3) 9 (24.3)
None 1 (5.3) 3 (33.3) 2 (22.2) 6 (16.2)
Quantiferon TB
Gold test
0 (0) 1 (11.1) 2 (22.2) 3 (8.1)
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Table 1 Responses to the survey questions in the three groups (Continued)
14 Do you treat a patient with
suspected TB on the basis of
a positive Quantiferon TB
Gold test alone
Frequently 3 (15.8) 1 (11.1) 2 (22.2) 6 (16.2)
Rarely 7 (36.8) 7 (77.8) 2 (22.2) 16 (43.2)
Sometimes 9 (47.4) 1 (11.1) 5 (55.6) 15 (40.5)
15 Do you treat a patient with
suspected TB on the basis of
a positive Mantoux test alone
Frequently 7 (36.8) 0 (0) 1 (11.1) 8 (21.6)
Rarely 5 (26.3) 8 (88.9) 4 (44.4) 17 (45.9)
Sometimes 7 (36.8) 1 (11.1) 4 (44.4) 12 (32.4)
16 In your experience, how do
you rate the results of
Quantiferon TB Gold test for
suspected TB in India with
the results projected by the
developed world
Comparable 10 (52.6) 2 (22.2) 2 (22.2) 14 (37.8) 0.163
Non-comparable 9 (47.4) 7 (77.8) 7 (77.8) 23 (62.2)
17 In your opinion, the limitation with Quantiferon TB Gold test is
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Mantoux test in such a scenario is not very clear. In
such situations, a combination of Mantoux test and
Quantiferon TB Gold test was more preferred than a
solo investigation as there is no gold standard for latent
tuberculosis.
This survey has many limitations. Firstly, the small
sample size raises questions of whether the responses
collected reflect actual practice patterns of specialists in
the rest of India. This population was chosen despite its
small size to elicit responses from only those specialists
who have used this test in the management of TB. Sec-
ondly, practice patterns regarding Mantoux and Quanti-
feron TB Gold may differ between individuals and hence
are not uniform. This may affect the overall perception
of this test to a small extent. Thirdly, this survey did not
get any information regarding the generation of test used
and the usefulness of this test in children and immuno-
compromised patients due to HIV. This is due to the
limited experience available on the usefulness of this test
in this subset of patients. Lastly, as only Quantiferon TB
Gold and the In-Tube assays are available in India, it is
difficult to get any data regarding the other IGRA test
(using the ELISpot technology) from a TB-endemic
country like India.Conclusions
From this survey, it is quite possible that there is a dif-
ference in the perception of QuantiFeron TB Gold test
by ophthalmologists, rheumatologists, and pulmonolo-
gists. The increased cost and limited data from India
with respect to interpretation of the results are the most
common limiting factors in using this test. Even with the
above limitations, this survey data can help researchers
plan prospective studies regarding the usefulness of this
test in TB-endemic areas in the future.Methods
Survey population
Nineteen uveitis specialists all over India, belonging to
the Uveitis Society of India, with experience in dealing
with patients with tuberculosis and who have used this
test since the last 2 years took the survey. Nine pulmo-
nologists and nine rheumatologists with at least 2 years
experience in using this test for TB also took the survey.
This population was chosen despite its small size to
elicit responses from only those specialists who have
used this test in the management of TB.
Survey
The survey included questions related to the type of tu-
berculosis seen in their practice, usage of this test in
their practice, their preferences for the basis of treat-
ment and technical and logistic issues pertaining to the
test, and the limitations of this test. The respondents
were asked to rate as ‘always, sometimes, or never.’ In
the section on the type of tuberculosis and the prefer-
ences for the basis of treatment, the respondents were
asked to rate as ‘frequent, sometimes, and rarely.’ The
survey was sent online (Google) to all the respondents.
Statistical methods
All of the statistical analysis was done using SPSS soft-
ware (version 15, Chicago, IL, USA). Both descriptive
analysis and independent variables were done using the
chi-square test, and all tests were done at 5% level of
significance.
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